Recent Updates
Recently added Catalysts

Eletriptan commercial

Phase 1

Undisclosed | Small molecule | Other |Viatris Inc.|Trials Updated: Jan 28, 2021

Eletriptan commercial target and mechanism

ModalitySmall molecule

Also known as Eletriptan commercial tablet

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLED
Total Trials1
Total Enrollment16

FDA Designations

No designations recorded

Eletriptan commercial clinical trials

Eletriptan commercial · 1 trial · 1 indication

Phase 1 1
NCT01139515Eletriptan Pharmacokinetics In Korean MalesHealthy
COMPLETED16 Analytics
PHASE1COMPLETED
Eletriptan Pharmacokinetics In Korean Males
Healthy
NCT0113951516
Unlock trial analytics

Study Endpoints

Primary Endpoints

Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)]
Pre-dosing, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hrs post dose (A,B,C) and additional 2.5,2.75,3.5,5,14,18 and 26 hrs post dose(D)

AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).

AUC From Time Zero to Last Quantifiable Concentration (AUClast)
Pre-dosing, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hrs post dose (A,B,C) and additional 2.5,2.75,3.5,5,14,18 and 26 hrs post dose (D)

Area under the plasma concentration-time curve from time zero (pre-dose) to the time of the last measurable concentration (AUClast).

Maximum Observed Plasma Concentration (Cmax)
Pre-dosing, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hrs post dose (A,B,C) and additional 2.5,2.75,3.5,5,14,18 and 26 hrs post dose (D)

Secondary Endpoints

Time to Reach Maximum Observed Plasma Concentration (Tmax)
Pre-dosing, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hrs post dose (A,B,C) and additional 2.5,2.75,3.5,5,14,18 and 26 hrs post dose (D)
Plasma Decay Half Life (t1/2)
Pre-dosing, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hrs post dose (A,B,C) and additional 2.5,2.75,3.5,5,14,18 and 26 hrs post dose (D)
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeBASIC_SCIENCE

Treatment Arms

ArmTypeDescription
Treatment AEXPERIMENTAL1 X 20 mg eletriptan
Treatment BEXPERIMENTAL1 X 40 mg eletriptan
Treatment CEXPERIMENTAL2 X 40 mg eletriptan
Treatment DEXPERIMENTAL1 X 40 mg tablet given 2 hr after initial 1 X 40 mg tablet dose

Interventions

NameTypeDescription
Eletriptan commercial tabletDRUG20 mg tablet, single dose
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 55 Years
SexMALE
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * healthy male subjects, 18-55 years old * Body Mass Index (BMI) of 17.5 to 30.5 kg/m2 * provide informed consent Exclusion Criteria: * blood pressure \>140/90 mm Hg * any condition possibly affecting drug absorption * positive urine drug screen

Countries:South Korea
Unlock Eligibility Criteria

Explore more on BiopharmaWatch

Viatris Inc. (VTRS)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with ECompanies A to ZEvery biotech and pharma company we track